Everolimus in Combination with Exemestane for Postmenopausal Women with Advanced Breast Cancer Who Are Refractory to Letrozole or Anastrozole: Results of the BOLERO-2 Phase III Trial

被引：0
|
作者：
Baselga, J. [1 ]
Campone, M. [2 ]
Sahmoud, T. [3 ]
Piccart, M. [4 ]
Burris, H. [5 ]
Rugo, H. [6 ]
Noguchi, S. [7 ]
Gnant, M. [8 ]
Mukhopadhyay, P. [9 ]
Hortobagyi, G. [10 ]
机构：
[1] Massachusetts Gen Hosp, Dept Oncol, Boston, MA 02114 USA
[2] Ctr Reg Rene Gauducheau, Dept Med Oncol, St Herblain, France
[3] Novartis Pharmaceut, Global Oncol Dev, Florham Pk, NJ USA
[4] Inst Jules Bordet, Dept Med, B-1000 Brussels, Belgium
[5] Sarah Cannon Res Inst, Drug Dev Program, Nashville, TN USA
[6] Univ Calif San Francisco, Dept Med Hematol Oncol, San Francisco, CA 94143 USA
[7] Osaka Univ, Dept Breast & Endocrine Surg, Osaka, Japan
[8] Med Univ Vienna, Dept Surg, Ctr Comprehens Canc, Vienna, Austria
[9] Novartis Pharmaceut, Oncol BDM, Florham Pk, NJ USA
[10] Univ Texas MD Anderson Canc Ctr, Dept Breast Med Oncol, Houston, TX 77030 USA
来源：
EUROPEAN JOURNAL OF CANCER | 2011年 / 47卷
关键词：
D O I：
10.1016/S0959-8049(11)70108-3
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9LBA
引用
收藏
页码：6 / +
页数：3
相关论文
共 50 条
  • [41] BOLERO-5: A phase II study of everolimus and exemestane combination in Chinese post-menopausal women with ER+/HER2-advanced breast cancer
    Shao, Z.
    Cai, L.
    Wang, S.
    Hu, X.
    Shen, K.
    Wang, H.
    Li, H.
    Feng, J.
    Liu, Q.
    Cheng, J.
    Wu, X.
    Wang, X.
    Li, H.
    Luo, T.
    Liu, J.
    Amin, K.
    Slimane, K.
    Qiao, Y.
    Liu, Y.
    Tong, Z.
    ANNALS OF ONCOLOGY, 2021, 32 : S463 - S463
  • [42] ACOSOG Z1031: A randomized phase II trial comparing exemestane, letrozole, and anastrozole in postmenopausal women with clinical stage II/III estrogen receptor-positive breast cancer
    Ellis, M. J.
    Babiera, G.
    Unzeitig, G. W.
    Marcom, P. K.
    Guenther, J. M.
    Deshryver, F. K.
    Allred, D. C.
    Suman, V.
    Hunt, K.
    Olson, J. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (18)
  • [43] Health-related quality of life of patients with advanced breast cancer treated with everolimus plus exemestane versus placebo plus exemestane in the phase 3, randomized, controlled, BOLERO-2 trial (vol 119, pg 1908, 2013)
    Burris, H. A.
    Lebrun, F.
    Rugo, J. S.
    CANCER, 2019, 125 (08) : 1387 - 1388
  • [44] Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2
    Piccart, M.
    Hortobagyi, G. N.
    Campone, M.
    Pritchard, K. I.
    Lebrun, F.
    Ito, Y.
    Noguchi, S.
    Perez, A.
    Rugo, H. S.
    Deleu, I.
    Burris, H. A., III
    Provencher, L.
    Neven, P.
    Gnant, M.
    Shtivelband, M.
    Wu, C.
    Fan, J.
    Feng, W.
    Taran, T.
    Baselga, J.
    ANNALS OF ONCOLOGY, 2014, 25 (12) : 2357 - 2362
  • [45] Incidence and time course of everolimus-related adverse events in postmenopausal women with hormone receptor-positive advanced breast cancer: insights from BOLERO-2
    Rugo, H. S.
    Pritchard, K. I.
    Gnant, M.
    Noguchi, S.
    Piccart, M.
    Hortobagyi, G.
    Baselga, J.
    Perez, A.
    Geberth, M.
    Csoszi, T.
    Chouinard, E.
    Srimuninnimit, V.
    Puttawibul, P.
    Eakle, J.
    Feng, W.
    Bauly, H.
    El-Hashimy, M.
    Taran, T.
    Burris, H. A., III
    ANNALS OF ONCOLOGY, 2014, 25 (04) : 808 - 815
  • [46] Everolimus Plus Exemestane in Postmenopausal Patients with HR+ Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis (vol 30, pg 870, 2013)
    Yardley, Denise A.
    Noguchi, Shinzaburo
    Pritchard, Kathleen I.
    Burris, Howard A., III
    Baselga, Jose
    Gnant, Michael
    Hortobagyi, Gabriel N.
    Campone, Mario
    Pistilli, Barbara
    Piccart, Martine
    Melichar, Bohuslav
    Petrakova, Katarina
    Arena, Francis P.
    Erdkamp, Frans
    Harb, Wael A.
    Feng, Wentao
    Cahana, Ayelet
    Taran, Tetiana
    Lebwohl, David
    Rugo, Hope S.
    ADVANCES IN THERAPY, 2014, 31 (09) : 1008 - 1009
  • [47] The efficacy and safety of neoadjuvant chemotherapy ± letrozole in postmenopausal women with locally advanced breast cancer: a randomized phase III clinical trial
    Mohammadianpanah, Mohammad
    Ashouri, Yaghoub
    Hoseini, Sare
    Amadloo, Niloofar
    Talei, Abdolrasoul
    Tahmasebi, Sedigheh
    Nasrolahi, Hamid
    Mosalaei, Ahmad
    Omidvari, Shapour
    Ansari, Mansour
    Mosleh-Shirazi, Mohammad Amin
    BREAST CANCER RESEARCH AND TREATMENT, 2012, 132 (03) : 853 - 861
  • [48] The efficacy and safety of neoadjuvant chemotherapy +/− letrozole in postmenopausal women with locally advanced breast cancer: a randomized phase III clinical trial
    Mohammad Mohammadianpanah
    Yaghoub Ashouri
    Sare Hoseini
    Niloofar Amadloo
    Abdolrasoul Talei
    Sedigheh Tahmasebi
    Hamid Nasrolahi
    Ahmad Mosalaei
    Shapour Omidvari
    Mansour Ansari
    Mohammad Amin Mosleh-Shirazi
    Breast Cancer Research and Treatment, 2012, 132 : 853 - 861
  • [49] Effects of exemestane and letrozole therapy on plasma concentrations of estrogens in a randomized trial of postmenopausal women with breast cancer
    Robarge, Jason D.
    Desta, Zereunesay
    Nguyen, Anne T.
    Li, Lang
    Hertz, Daniel
    Rae, James M.
    Hayes, Daniel F.
    Storniolo, Anna M.
    Stearns, Vered
    Flockhart, David A.
    Skaar, Todd C.
    Henry, N. Lynn
    BREAST CANCER RESEARCH AND TREATMENT, 2017, 161 (03) : 453 - 461
  • [50] Effects of exemestane and letrozole therapy on plasma concentrations of estrogens in a randomized trial of postmenopausal women with breast cancer
    Jason D. Robarge
    Zereunesay Desta
    Anne T. Nguyen
    Lang Li
    Daniel Hertz
    James M. Rae
    Daniel F. Hayes
    Anna M. Storniolo
    Vered Stearns
    David A. Flockhart
    Todd C. Skaar
    N. Lynn Henry
    Breast Cancer Research and Treatment, 2017, 161 : 453 - 461
12345